Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2

Authors: Shaoyi Cao, Huaqiu Li, Xiaoyan Ye, Xinxing Xing, Yonghuan Xie, Xiangfeng Zeng, Hongjiao Liu, Xing Zhong, Xinyi Yang, Wenxiu Xing, Cairong Zhu, Xiaoping Wu

Source: European Journal of Medical Research, Vol 29, Iss 1, Pp 1-17 (2024)

Subject Terms: Apoptosis, Cyclooxygenase-2 (COX-2), Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance, Pyroptosis, Shikonin, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/2047-783X

Access URL: https://doaj.org/article/f604bf4b40e8421eb7745e344d4e3db6

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations

Authors: Han X, You Y, Guo X, Ji Y, Nie K

Source: International Journal of General Medicine, Vol Volume 17, Pp 5503-5510 (2024)

Subject Terms: epidermal growth factor receptor tyrosine kinase inhibitor, uncommon egfr mutations, non-small-cell lung cancer, afatinib, bevacizumab, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.dovepress.com/afatinib-combined-with-bevacizumab-in-the-treatment-of-patients-with-n-peer-reviewed-fulltext-article-IJGM; https://doaj.org/toc/1178-7074

Access URL: https://doaj.org/article/a4bc11e53e974b5dbabf473041dc81f1

Predictive value of direct bilirubin and total bile acid in lung adenocarcinoma patients treated with EGFR-TKIs

Authors: Yuting Li, Bicheng Wang, Shihong Fei, You Qin

Source: BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-11 (2024)

Subject Terms: Total bile acid, Direct bilirubin, Epidermal growth factor receptor-tyrosine kinase inhibitor, Progression-free survival, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2466

Access URL: https://doaj.org/article/dbe1663ed75f48778633b41d79ff3c1a

Evaluation of the prognostic value of the new 9th edition Tumor-Node-Metastases (TNM) staging system for epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients with bone metastases

Authors: Jin Peng, Fang Hu, Xiaowei Mao, Yanjie Niu, Meili Ma, Liyan Jiang

Source: BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-12 (2024)

Subject Terms: Lung adenocarcinoma, Updated stage classification, Prognosis, Epidermal growth factor receptor tyrosine kinase inhibitor, Bone metastases, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2466

Access URL: https://doaj.org/article/82ff8c6d670744eaa70a2d8329d79185

Significance of Runt-related transcription factor 1 and Notch1 expression in non-small-cell lung cancer: involvement in epithelial-mesenchymal transition and epidermal growth factor receptor-tyrosine kinase inhibitor therapy resistance

Authors: Heba M Rashad, Hanan Ahmed, Samar N Mohamed, Hiam A. Eleleimy, Ebtehal M Abdel-Aal

Source: Egyptian Journal of Chest Disease and Tuberculosis, Vol 73, Iss 3, Pp 290-301 (2024)

Subject Terms: epidermal growth factor receptor–tyrosine kinase inhibitor, epithelial–mesenchymal transition, notch1, runt-related transcription factor1, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://journals.lww.com/ecdt/fulltext/2024/07000/significance_of_runt_related_transcription_factor.12.aspx; https://doaj.org/toc/2090-9950

Access URL: https://doaj.org/article/c50ad990d0ef4ca280a0be0f5f96b196

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance

Authors: Jin Tian, Zhiqi Shi, Lili Zhao, Peng Liu, Xiaojun Sun, Lin Long, Jianhua Zang, Jun Xiao

Source: The Clinical Respiratory Journal, Vol 18, Iss 12, Pp n/a-n/a (2024)

Subject Terms: EGFR‐TKIs resistance, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), immune checkpoint inhibitors, immunotherapy, non‐small cell lung cancer (NSCLC), Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://doaj.org/toc/1752-6981; https://doaj.org/toc/1752-699X

Access URL: https://doaj.org/article/7e7804000d2e4b088589d102ea1f31a5

Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report

Authors: Yoshihiro Go, Chinatsu Yoshizaki, Yuki Yoshida, Shiho Nohmi, Rui Kusakado, Yuichiro Saito, Kensuke Izumizaki, Takafumi Ogawa, Takashi Suzuki, Fumihiro Yamaguchi

Source: Current Problems in Cancer: Case Reports, Vol 16, Iss , Pp 100329- (2024)

Subject Terms: Epidermal growth factor receptor-tyrosine kinase inhibitor, Non-small cell lung cancer, EGFR L858R mutation, Long-term survival, Postoperative recurrence, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666621924000516; https://doaj.org/toc/2666-6219

Access URL: https://doaj.org/article/1065f93686de47658f71f7a8381fa71c

Correlation between circulating CD4+CD45RA+CD62L+ T cells and prognosis of metastatic non-small cell lung cancer treated with EGFR-TKI

Authors: CAO Chenxin, TANG Hui, GENG Ruixuan, GUO Fuping, BAI Chunmei, WANG Yingyi, LI Taisheng

Source: Jichu yixue yu linchuang, Vol 44, Iss 5, Pp 658-664 (2024)

Subject Terms: epidermal growth factor receptor-tyrosine kinase inhibitor (egfr-tki), lymphocyte subset, lung cancer, cd4+cd45ra+cd62l+ t cell, prognosis, Medicine

File Description: electronic resource

Relation: http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2024-44-5-658.pdf; https://doaj.org/toc/1001-6325

Access URL: https://doaj.org/article/de9dcede191e425c99351fb7b6268578

The impact of comorbidities, neutrophil-to-lymphocyte ratio, and drug toxicities on quality of life in lung cancer patients receiving EGFR-TKI therapy

Authors: Jung-Yueh Chen, Sheng-Kai Liang, Tzu-Yi Chuang, Chia-Yu Chu, Chia-Hung Tu, Yu-Jo Yeh, Yu-Feng Wei, Kuan-Yu Chen

Source: Journal of the Formosan Medical Association, Vol 123, Iss 2, Pp 198-207 (2024)

Subject Terms: Adverse events, Comorbidity, Epidermal growth factor receptor tyrosine kinase inhibitor, Non-small cell lung cancer, Quality of life, Neutrophil-to-lymphocyte ratio, Medicine (General), R5-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0929664623002917; https://doaj.org/toc/0929-6646

Access URL: https://doaj.org/article/35cd2d64adf249559b93739c6530ae0d

Bilateral keratitis associated with afatinib therapy

Authors: Ya-Tung Liu, Chen-Wei Lin, Chi-Chin Sun, Shih-Chieh Shao, Nan-Ni Chen

Source: Taiwan Journal of Ophthalmology, Vol 14, Iss 1, Pp 121-124 (2024)

Subject Terms: afatinib, epidermal growth factor receptor-tyrosine kinase inhibitor, keratitis, Ophthalmology, RE1-994

File Description: electronic resource

Relation: http://www.e-tjo.org/article.asp?issn=2211-5056;year=2024;volume=14;issue=1;spage=121;epage=124;aulast=Liu; https://doaj.org/toc/2211-5056; https://doaj.org/toc/2211-5072

Access URL: https://doaj.org/article/40f7934395794b0695d91c832981f2d6

A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma

Authors: Xue Han, Lan Liang, Chenming He, Qinyou Ren, Jialin Su, Liang Cao, Jin Zheng

Source: BMC Complementary Medicine and Therapies, Vol 23, Iss 1, Pp 1-23 (2023)

Subject Terms: Lung adenocarcinoma, ZiLongJin Tablet, Epidermal growth factor receptor-tyrosine kinase inhibitor, Real-world study, Network pharmacology, Molecular docking simulation, Other systems of medicine, RZ201-999

File Description: electronic resource

Relation: https://doaj.org/toc/2662-7671

Access URL: https://doaj.org/article/3823770dc37a47bf8865d464d9f65823

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review

Authors: Xiaofei Gu, Yonghong Zhong, Huaqiong Huang

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), rechallenge, osimertinib, non-small cell lung cancer (NSCLC), interstitial lung disease (ILD), Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1410684/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/596cde0bed4f47279799f48de255daa5

Impact of sequential (first- to third-generation) EGFR-TKI treatment on corrected QT interval in NSCLC patients

Authors: Tian Gan, Jindong Chen, Hao Wang, Conghui Shang, Siqi Xi, Zixu Fan, Ben He, Min Zhang, Liang Zhao

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: non-small cell lung cancer, epidermal growth factor receptor-tyrosine kinase inhibitor, corrected QT interval, risk factor, advanced lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1330165/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/55d2d51f4da2463bbf0ee2f3d05110ed

Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study

Authors: Shuai Liang, Hanyu Wang, Yingyun Zhang, Haixia Tian, Chengming Li, Dong Hua

Source: Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)

Subject Terms: epidermal growth factor receptor‐tyrosine kinase inhibitor, exon 19 deletion, exon 21 L858R mutation, radiotherapy, Stage IV lung adenocarcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/fe877c2c322344bda60d0f0b36daf2c9

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

Authors: Shu-Ling Zhang, Xiao-Fang Yi, Le-Tian Huang, Li Sun, Jie-Tao Ma, Cheng-Bo Han

Source: BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)

Subject Terms: Adjuvant therapy, Epidermal growth factor receptor tyrosine kinase inhibitor, Meta-analysis, Non-small-cell lung cancer, Mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/8181fd1434c0488bb08488721b45b3e6

A Case of Rapidly Progressive Diabetic Nephropathy Induced by Osimertinib

Authors: Kazunori Karasawa, Ken-ichi Akiyama, Taro Akihisa, Yoei Miyabe, Kosaku Nitta, Junichi Hoshino

Source: Case Reports in Nephrology and Dialysis, Vol 13, Iss 1, Pp 104-112 (2023)

Subject Terms: endothelial nitric oxide synthase, epidermal growth factor receptor-tyrosine kinase inhibitor, diabetic nephropathy, podocyte, vascular endothelial growth factor, Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: https://beta.karger.com/Article/FullText/531015; https://doaj.org/toc/2296-9705

Access URL: https://doaj.org/article/16bd87c3aca24f90969a5dd1a838d151

Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance

Authors: Juan Zhou, Xiangling Chu, Jing Zhao, Mengqing Xie, Jing Wu, Xin Yu, Yujia Fang, Yazhou Li, Xiyan Li, Chunxia Su

Source: Biological Procedures Online, Vol 25, Iss 1, Pp 1-13 (2023)

Subject Terms: Non-small cell lung cancer (NSCLC), Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance, Immune checkpoint inhibitor (ICI) plus chemotherapy, Peripheral blood mononuclear cell (PBMC), Medicine (General), R5-920, Biology (General), QH301-705.5

File Description: electronic resource

Relation: https://doaj.org/toc/1480-9222

Access URL: https://doaj.org/article/67c780f444bc46258dd9398bbbe65e60

Onset of takotsubo syndrome induced by osimertinib in a patient with lung adenocarcinoma

Authors: Shouichi Okamoto, Mariko Shinomiya

Source: Respiratory Medicine Case Reports, Vol 50, Iss , Pp 102056- (2024)

Subject Terms: Epidermal growth factor receptor-tyrosine kinase inhibitor, Lung cancer, Osimertinib, Takotsubo syndrome, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2213007124000790; https://doaj.org/toc/2213-0071

Access URL: https://doaj.org/article/03ff8b859c684342ac48debeb868d16f

Osimertinib-associated erythema dyschromicum perstans–like eruption: A case series

Authors: Christina S. Oh, BA, Michael J. Martinez, BS, Shane Meehan, MD, Daniel Gutierrez, MD, Ian W. Tattersall, MD, PhD

Source: JAAD Case Reports, Vol 35, Iss , Pp 28-32 (2023)

Subject Terms: ashy dermatosis, epidermal growth factor receptor tyrosine kinase inhibitor, erythema dyschromicum perstans, hyperpigmentation, osimertinib., Dermatology, RL1-803

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352512623000711; https://doaj.org/toc/2352-5126

Access URL: https://doaj.org/article/9fe64ee15bdd463cb1dc8ebada9ac48e

Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations

Authors: Ling Zhang, Yunhong You, Xueli Liu, Fengjuan Liu, Keke Nie, Youxin Ji

Source: Thoracic Cancer, Vol 14, Iss 15, Pp 1355-1361 (2023)

Subject Terms: brain metastasis, epidermal growth factor receptor tyrosine kinase inhibitor, non‐small cell lung cancer, osimertinib, target therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714

Access URL: https://doaj.org/article/1f806dd5d92b4f44877bf1b180caaa15